Related Experiment Video

Updated: Apr 17, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

13.2K

Cross-platform meta-analysis of multiple gene expression profiles identifies novel expression signatures in acquired

Young Seok Lee1, Seung Won Ryu1, Se Jong Bae1

  • 1Department of Biochemistry, Konkuk University School of Medicine, Seoul 143‑701, Republic of Korea.

Oncology Reports
|February 20, 2015
PubMed

Insights

This study identified 413 differentially expressed genes linked to anthracycline resistance in breast cancer. Key biological processes and pathways were uncovered, offering new insights into treatment limitations.

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Anthracyclines are vital chemotherapy drugs for breast cancer.
  • Acquired resistance to anthracyclines significantly limits their clinical effectiveness.
  • Understanding the genetic basis of this resistance is crucial for improving treatment outcomes.

Purpose of the Study:

  • To identify differentially expressed genes (DEGs) associated with anthracycline resistance in human breast cancer cells.
  • To elucidate the biological processes and molecular pathways involved in the development of this resistance.
  • To provide a foundation for further research into overcoming anthracycline resistance.

Main Methods:

  • A meta-analysis of public microarray datasets was conducted using RankProd in R.
  • Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases were utilized for enrichment and pathway analyses.
  • A protein-protein interaction (PPI) network was constructed using Cytoscape software.

Main Results:

  • The meta-analysis identified 413 DEGs related to anthracycline resistance, with 374 novel findings.
  • GO analysis revealed enrichment in terms like 'response to steroid metabolic process' and 'hormone stimulus'.
  • Significant pathways included steroid hormone biosynthesis, drug metabolism (cytochrome P450), and cytokine-cytokine receptor interaction. TRIM29, VTN, CCNA1, and KPNA5 were key interacting proteins.

Conclusions:

  • This meta-analysis offers a comprehensive overview of gene expression changes in anthracycline-resistant breast cancer.
  • The identified genes and pathways provide potential targets for future therapeutic strategies.
  • Further functional studies are warranted to validate these findings and explore clinical applications.

More Related Videos

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.7K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72